Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
GE-Portuguese Journal of Gastroenterology
versión impresa ISSN 2341-4545
Resumen
SANTOS, Sara et al. Tofacitinib: An Option for Acute Severe Ulcerative Colitis?. GE Port J Gastroenterol [online]. 2022, vol.29, n.2, pp.56-58. Epub 15-Sep-2022. ISSN 2341-4545. https://doi.org/10.1159/000514781.
Tofacitinib has emerged as a new option for ulcerative colitis. Its rapid absorption, metabolism, and clinical improvement make it an interesting option for rescue therapy in acute severe ulcerative colitis (ASUC), a situation with limited therapeutic options in patients with a long-term disease course and multiple drug failure. The management of ASUC in this setting becomes challenging, underlying the need for new drugs and data on their efficacy and safety. We describe 2 cases of acute episodes in which tofacitinib was used as a rescue therapy.
Palabras clave : Acute severe ulcerative colitis; Tofacitinib.